Noxopharm Ltd has released a press release.
Pre-clinical Data Supports a Role for Veyonda in COVID-19
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Noxopharm
- NOXCOVID Program to Expand After Positive Phase 1 Results
- Noxopharm: Pre-clinical Study Confirms Survival Advantage of Combination LuPSMA Therapy in Prostate Cancer
- NOX and US Govt Peak Cancer Agency Announce Collaboration
- Veyonda Survival Advantage in LuPSMA Therapy Confirmed
- June 2021 Quarterly Activities Report and Appendix 4C
Later from Noxopharm
- Phase I Clinical Trial Shows Anti-Inflammatory Response in COVID-19 Patients
- Preclinical Data Further Supports Anti-Inflammatory Role of Idronoxil in the Treatment of COVID-19
- Veyonda Achieves Important U.S. Patent Claims
- September 2021 Quarterly Activities Report and Appendix 4C
- Patent Granted for Veyonda and Low Dose Chemotherapy
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm